ReviewCurrent atherosclerosis reports2025

Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field.

Francesco Di Giacomo-Barbagallo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.